Biotech/ Pharma Stocks To Watch; Friday's Gainers: (NASDAQ:PARDD), (NASDAQ:LXRX), (NASDAQ:ACHN), (NASDAQ:TNGN)

Point Roberts, WA - December 12, 2011- Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues an investor alert for some of the top trading stocks in the sector for Friday, December 09, 2011.

Poniard Pharmaceuticals, Inc. (NASDAQ:PARDD) was the biggest gainer within the sector and soared 13.91% to close at $3.85, with most of gains coming in the final hour of the trading session without any major news. The stock was probably bounced back after falling over 30% during the past week.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) ended higher by 13.39% to end at $1.27 on very unusual volume 919K shares, compared to its average volume of 566K shares. The stock bounced back from its recent fall and closed the week with gains of over 5%.
Tengion, Inc. (NASDAQ:TNGN) added 11.63% and closed at $0.475, extending its weekly gains to over 18% on increased volume. Last week, the company announced the appointment of John L. Miclot as its President and Chief Executive Officer (CEO)
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) moved up by 10.10% to close at $7.52 on high volume and recovered all its losses earlier during the week. Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.
Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) soared 9.57% to finish at $8.13, bouncing back from its recent fall. Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Research and trade biotech and pharma stocks with the global stock directory:
http://www.investorideas.com/BIS/Stock_List.asp
Visit our biotech stocks research page:
http://www.investorideas.com/BIS/
Investor Research Tools;
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas
Get 13 of the best stock directories online and investing ideas and stock alerts
Research biotech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more. Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . Disclosure:
www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com

Thursday's Biotech Stocks to Watch; (NASDAQ:AFFY), (NASDAQ:DARA), (NASDAQ:SGEN), (NASDAQ:CTIC)

News about Affymax, Inc. (NASDAQ:AFFY)

Point Roberts, WA - December 9, 2011 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues an investor alert for some of the top trading stocks in the sector for Thursday December 08, 2011.

Affymax, Inc. (NASDAQ:AFFY) shares gained 2.12 (36.22%) to end at $7.98 after A Food and Drug Administration panel voted in favor of the biotech drugmaker's experimental treatment for patients with anemia.
DARA Biosciences Inc. (NASDAQ:DARA) ended higher by 0.11 (9.65%) to close at $1.25 on very unusual volume after the company announced that Richard A. Franco, Sr. will retire as Chairman, President and Chief Executive Officer and as a director effective as of December 16, 2011.
Seattle Genetics, Inc. (NASDAQ:SGEN) rose 0.88 (5.15%) and closed at $17.98, extending its weekly gains to over 19% on increased volume. The company announced today that management will present at the following upcoming investor conference. Oppenheimer 22nd Annual Healthcare Conference Wednesday, December 14, 2011 at 2:10 p.m. Eastern Time in New York, NY
Synageva BioPharma Corp. (NASDAQ:GEVA) moved higher by 0.77 (4.10%) to end at $19.57 and made a new 52-week high of $19.74, extending its weekly gains to over 15% on heavy volume. The stock has a 52-week range of $10.04-$19.74.
Cell Therapeutics, Inc. (NASDAQ:CTIC) climbed 0.03 (2.22%) to close at $1.38 on high volume. Today morning, the company announced that it has entered into an agreement to sell, subject to customary closing conditions, $20 million of shares of its Series 14 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to two institutional investors.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Research and trade biotech and pharma stocks with the global stock directory:
http://www.investorideas.com/BIS/Stock_List.asp
Visit our biotech stocks research page:
http://www.investorideas.com/BIS/
Investor Research Tools;
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas
Get 13 of the best stock directories online and investing ideas and stock alerts
Research biotech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more. Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com

Biotech/Pharma Stock Trading Alert: Affymax (NasdaqGS: AFFY) Trades Up 37% on FDA Advisory Committee Vote

POINT ROBERTS, December 8, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, issues a trading alert for Biotech/Pharma stock, Affymax, Inc. (NasdaqGS: AFFY) trading at $8.06, up 2.20 (37.50%) 2:09PM EST. The stock has a high of $8.45 in today’s trading session.

Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Company Limited (TSE:4502), announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 15 to 1, with 1 abstention, that peginesatide demonstrated a favorable benefit/risk profile for use in the treatment of dialysis patients with anemia due to chronic kidney disease (CKD).


About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Research and trade biotech and pharma stocks with the global stock directory :
http://www.investorideas.com/BIS/Stock_List.asp

Visit our biotech stocks research page:
http://www.investorideas.com/BIS/

Investor Research Tools;
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp

Join Investor Ideas
Get 13 of the best stock directories online and investing ideas and stock alerts
Research biotech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more.  Join: http://www.investorideas.com/membership/

Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp

800-665-0411 - Source – www.Investorideas.com

Tuesday's Biotech/ Pharma Stocks to Watch; (NASDAQ:PPHM), (NASDAQ:BPAX), (NASDAQ:ONTY), (NASDAQ:CTIC)

Point Roberts, WA - December 7, 2011 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues an investor alert for some of the top trading stocks in the sector for Tuesday, December 06, 2011.

Peregrine Pharmaceuticals (NASDAQ:PPHM) was the biggest percentage gainer and soared 0.21 (21.02%) to $1.21 after news that Peregrine Pharmaceuticals Inc's experimental lung cancer therapy reduced more tumors than standard treatment in a mid-stage study.
BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) ended flat at $2.56 on high volume of 1.52 million shares. The stock has gained above 15% over the past week. The stock was featured at The Street.com in a video - The Next Big Things In Biotech: Biosante. Several analysts and newsletters are watching Biosante stock as catalysts that can move it higher come into play in December. BioSante's lead products include LibiGel ® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA).
Oncothyreon Inc.(NASDAQ:ONTY) traded higher by 1.02 (14.29%) and closed at $8.16 after gaining over about 4% in the previous trading session on news that Bob Kirkman, the CEO of the company took an unexplained medical leave from the company back in September. The company said at the time he'd return for the fourth quarter of 2011; he's back on the job as CEO.
Cell Therapeutics, Inc.(NASDAQ:CTIC) moved higher by 13.04% to $1.30 following news the company announced that the U.S. Food and Drug Administration's Division of Oncology Products 1 has notified CTI that CTI's October 2011 resubmitted New Drug Application ("NDA") is considered complete.
Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) climbed 0.83 (7.79%) to $083 on high volume. In the pre-market session, the stock added another 12% after the company provided update on clinical progress with sapacitabine in solid tumors including activity in BRCA mutation-positive patients.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Research and trade biotech and pharma stocks with the global stock directory:
http://www.investorideas.com/BIS/Stock_List.asp
Visit our biotech stocks research page:
http://www.investorideas.com/BIS/
Investor Research Tools;
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas
Get 13 of the best stock directories online and investing ideas and stock alerts
Research biotech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more. Join:   http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . Disclosure: BioSante (BPAX) is a paid online advertising company on Investorideas.com (six thousand five hundred for three months)
www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com

Biotech and Pharma Stock Alert; Aethlon Medical (OTC: AEMD) Announces Approval and Initiation of Cancer Research Study to Target Tumor-Secreted Exosomes

SAN DIEGO - December 6, 2011 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that a cancer research study to test the ex vivo effectiveness of the Aethlon Hemopurifier® to capture tumor-secreted exosomes from the blood of advanced-stage cancer patients has received institutional review board approval to begin studies at the Sarcoma Oncology Center, based in Santa Monica, California . The study will enroll up to 25 patients with metastatic cancer, including those with non-small cell lung cancer, prostate cancer, melanoma, head and neck cancer, and sarcoma. Testing of blood samples provided by three enrolled sarcoma patients has already been initiated. The study goal is to establish the first validation that a medical device, the Aethlon Hemopurifier®, can effectively capture tumor-secreted exosomes from the blood of cancer patients. Successful study outcomes would provide a basis for follow-on human treatment studies in cancer patients.

Tumor-secreted exosomes, which are not addressed by drug therapy, assist cancerous tumors in evading the immune response and are implicated in the survival, growth, and metastasis of cancer. The Aethlon Hemopurifier® is a first-in-class medical device with broad-spectrum capabilities against viral pathogens, including HIV and Hepatitis C virus (HCV). The device has also demonstrated the ability to capture tumor-secreted exosomes from cell culture and human ascites fluids. At present, the Hemopurifier® is being evaluated in human studies as an adjunct therapy to improve outcomes of HCV patients receiving interferon therapy.
The Sarcoma Oncology Center is a highly sought after research center for the clinical testing of new therapeutic candidates against sarcomas and other forms of cancer. Dr. Sant Chawla , the lead investigator of the study is a recognized authority in the sarcoma oncology field.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT� System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT� product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome� to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT� system including the ability to introduce a targeted breast cancer therapy known as HER2osome�, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the Hemopurifier's® ability to capture tumor-secreted exosomes and the impact it may have on disease conditions, the ability to successfully complete the Medanta HCV study and achieve positive results, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jody Cain
Senior Vice President, Lippert/Heilshorn & Associates
310.691.7100
jcain@lhai.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com

AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page

Disclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) is a paid advertising client ($one thousand five hundred per month, $five thousand per month in 144 stock)

Biotech stocks News; BioSante Pharmaceuticals (NASDAQ: BPAX) Announces Issuance of New LibiGel® Method of Use Patent

LINCOLNSHIRE, Ill. - November 29, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the issuance of a new U.S. patent covering the �method of use� of LibiGel (testosterone gel) for treating female sexual dysfunction (FSD) and hypoactive sexual desire disorder (HSDD). The patent covers methods for treating FSD and HSDD and also includes using a metered dosage device to deliver the defined dose of the testosterone formulation in LibiGel. U.S. Patent No. 8,067,399, which issued today, will expire on December 29, 2028. The two named inventors of this new patent are a current and a former employee of BioSante.

"We are very pleased that this new LibiGel patent has issued. The patent protects the use of LibiGel in treating FSD and HSDD, and the bottle we used in our clinical work, as well as in the intended commercial product, and extends our patent protection to the end of 2028,� said Stephen M. Simes, BioSante president and CEO. �Our objective has been to continue to strengthen our intellectual property covering LibiGel and this patent is a major achievement in that direction."
About LibiGel®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD). The completed Phase III efficacy trials are double-blind, placebo-controlled trials that enrolled over 500 surgically menopausal women each for six-months of therapy, approximately half of whom were taking concomitant estrogen therapy and half of whom took no concomitant estrogen therapy. The completed efficacy trials were conducted according to an FDA-agreed special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
In addition, BioSante is conducting the Phase III LibiGel safety study, a randomized, double-blind, placebo-controlled, multi-center, cardiovascular (CV) events and breast cancer study that has completed enrollment of 3,656 women and has accrued over 5,100 women-years of exposure, to date. The study will continue for a total of five years; however, BioSante will use the safety study data as part of an NDA submission after the last subject enrolled has completed 12 months of exposure to LibiGel or placebo.
The LibiGel safety study is tracking a predefined list of CV events, in agreement with the FDA, including CV death, myocardial infarction and stroke in women 50 years of age or older and suffering from at least two CV risk factors including hypertension and diabetes. The objective of the safety study is to demonstrate the relative safety of testosterone compared to placebo in the number of CV events. The incidence of breast cancer also is being tracked over the course of the study. The study represents the largest data base of the safety of testosterone in women.
Upon completion of the statistical analyses of efficacy trials and the safety study, BioSante intends to submit an NDA to the FDA, requesting approval of LibiGel for the treatment of HSDD in menopausal women. The NDA submission is targeted for the fourth quarter of 2012.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development according to a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as �will,� �continue,� �could,� �believe,� �intends,� �continue,� �expects,� �anticipates,� �estimates,� �may,� other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
Harris D. McKinney, Inc.
Alan Zachary
312-506-5220
azachary@harrisdmckinney.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp  
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp  
Source: Investorideas.com, BioSante, Investorideas.com
800 665 0411 cvanzant@investorideas.com

Biotech Investor Alert for (OTC: AEMD), (Nasdaq:VRUS), (VRTX); Hepatitis C Virus (HCV) Treatments

POINT ROBERTS - November 28, 2011 - www.InvestorIdeas.com issues a biotech investor alert for Pharmasset, Inc. (Nasdaq:VRUS), Vertex Pharmaceuticals (VRTX) and Aethlon Medical, Inc. (OTCBB: AEMD), three stocks involved in the treatment of Hepatitis C Virus (HCV).

Over 170 million people worldwide are chronically infected with Hepatitis C. The sector made headlines earlier this week as Pharmasset, Inc. (Nasdaq:VRUS), traded up over 84% on acquisition news.
Gilead Sciences, Inc. (Nasdaq:GILD) and Pharmasset, Inc. (Nasdaq:VRUS) reported the companies have signed a definitive agreement under which Gilead will acquire Pharmasset for $137 per share in cash.
Pharmasset (Nasdaq:VRUS) has three clinical-stage product candidates for the treatment of chronic hepatitis C virus (HCV) advancing in trials in various populations. The company's lead product candidate, PSI-7977, an unpartnered uracil nucleotide analog, has recently been advanced into two Phase 3 studies in genotype 2 and 3 patients. Both studies will utilize 12 weeks of treatment with PSI-7977 in combination with ribavirin. One study will compare this all-oral regimen against 24 weeks of the standard-of-care pegylated interferon/ribavirin in treatment-naïve patients, and the second study will compare the all-oral regimen to placebo in interferon-intolerant/ineligible patients. A third Phase 3 study in genotype 1 patients will be initiated in the second half of 2012, the design of which is dependent on the outcome of Phase 2 studies which are evaluating PSI-7977 in various combinations in genotype 1-infected patients. If successful, this strategy could lead to an initial U.S. regulatory approval of PSI-7977 in 2014. PSI-938, an unpartnered guanosine nucleotide analog, is being tested in a Phase 2b interferon-free trial as monotherapy and in combination with PSI-7977 in subjects with HCV of all viral genotypes. Mericitabine (RG7128), a cytidine nucleoside analog, is partnered with Roche and is being evaluated in three Phase 2b trials. Roche is responsible for all aspects of the development of mericitabine.
Gilead's research and development portfolio includes seven unique molecules in various stages of clinical development for the treatment of HCV.
James A. Joyce, Chairman and CEO of Aethlon Medical, Inc. (OTCBB: AEMD) recently updated shareholders on November 16 th, "Our Hemopurifier® has demonstrated broad-spectrum capabilities against viral pathogens, including HCV, the human immunodeficiency virus (HIV), and a variety of tested bioterror and pandemic threats. Specific to treating HCV, we previously conducted studies that demonstrated the safe administration of our Hemopurifier® in HCV-infected dialysis patients whose average viral load reductions exceeded 50% during each four-hour treatment. These results were obtained in the absence of any drug therapy."
Full news : http://finance.yahoo.com/news/Aethlon-Medical-Releases-prnews-4279719933.html?x=0&l=
Vertex Pharmaceuticals Inc (VRTX ) announced earlier in November its interim results from ZENITH, an ongoing Phase 2 study designed to assess the safety, tolerability and efficacy of multiple 12- and 24-week response-guided treatment regimens with VX-222 (100mg or 400mg), its lead polymerase inhibitor in development, in combination with INCIVEK™ (telaprevir ) tablets, pegylated-interferon and ribavirin in people with genotype 1 chronic hepatitis C who were new to treatment. On the basis of the results announced today and previously announced data from other treatment arms of the ZENITH study, Vertex intends to start a Phase 3 study to evaluate a total treatment duration of 12 weeks with this four-drug regimen in treatment naïve and relapser patients with genotype 1 chronic hepatitis C.
More about Aethlon Medical (OTCBB: AEMD)
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Visit the AEMD showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get biotech news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC (OTC BB: AEMD) Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock) Effective March 15, 2011      
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com